Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

Bevacizumab 18Paclitaxel 17pembrolizumab 14Specimen Handling 14Carboplatin 13Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11Cyclophosphamide 10Gemcitabine 9olaparib 8fludarabine 8Topotecan 8Biopsy 8Fulvestrant 6palbociclib 5Taxes 5Nivolumab 5Immunoglobulin G 5Doxorubicin 5Disulfides 5aldesleukin 4trastuzumab deruxtecan 3niraparib 3binimetinib 3Oxaliplatin 3Cisplatin 3AZD5305 3sarilumab 2nilotinib 2neratinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Bupropion × 30 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡